AstraZeneca's Drug Olaparib Appears to Benefit Targeted Prostate Cancer Patients
AstraZeneca’s (NYSE:AZN) drug olaparib appears promising for a targeted group of prostate cancer patients, united by a distinct genetic mutation.
Scientists in the U.K. say that AstraZeneca’s ($AZN) drug olaparib, approved by the FDA late last year to treat ovarian cancer and sold as Lynparza, has demonstrated distinct signs of efficacy in a small and very targeted group of prostate cancer patients who share a distinct type of genetic mutation.
Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor, which blocks enzymes involved in DNA repair. It’s used among women suffering from ovarian cancer who have BRCA gene mutations identified through a genetic test.
The team of researchers from the Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust recruited 49 treatment-resistant, metastatic prostate cancer patients and tested the drug on them. What excited them was that 14 of the patients who responded to the drug also had genetic mutations linked with DNA repair, a profile shared by 16 patients.
“This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread,” noted Áine McCarthy, the science information officer at Cancer Research UK, which helped fund the work, in a statement. “The hope is that this approach could help save many more lives in the future.” The results were published in The New England Journal of Medicine.
Click here to read the full article on Fierce Biotech.
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1807.22 | -1.19 | |
Silver | 19.93 | +0.07 | |
Copper | 3.57 | -0.14 | |
Palladium | 1941.50 | -3.50 | |
Platinum | 887.00 | +1.00 | |
Oil | 110.57 | +4.81 | |
Heating Oil | 3.95 | +0.12 | |
Natural Gas | 5.84 | +0.23 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.